![]() |
|
Increased Severity of Lower Urinary Tract Symptoms and Daytime Somnolence in Primary Sjögren's Syndrome
JENNIFER WALKER, TOM GORDON, SUE LESTER, SARAH DOWNIE-DOYLE, DOUG McEVOY, KEVIN PILE, SALLY WATERMAN, and MAUREEN RISCHMUELLER
ABSTRACT.
Methods. Female patients were recruited from rheumatology outpatient clinics at 2 hospitals. The American Urological Symptom Index (AUA-7), Epworth Sleepiness Scale, and FACIT-F fatigue self-administered instruments were employed. Results were obtained for 76 patients with primary SS and 43 controls (response rates 85% and 67%, respectively). The patient groups were matched for parity, hormone replacement and diuretic therapy, and number of bladder operations and urinary tract infections, although OA patients were slightly older. Results. AUA-7 urological symptoms were more severe in patients with primary SS compared to OA controls (p = 0.039). Severe urological symptoms were reported by 61% of primary SS patients compared with 40% of OA controls. This difference was predominantly attributable to bladder irritability associated with urgency (p = 0.015) and not nocturia (p = 0.85). Epworth Sleepiness Scale scores were also more severe in primary SS patients compared to OA controls (p = 0.02), independent of nocturia. The FACIT-F fatigue severity scores were not significantly different between patient groups (p = 0.14). Conclusion. Urological symptoms and daytime somnolence may be previously unrecognized symptoms of primary SS. These symptoms are consistent with functional disturbances of muscarinic receptors, possibly mediated by muscarinic receptor autoantibodies. (J Rheumatol 2003;30:2406-12) Key Indexing Terms:
AUTOIMMUNE DISEASE
From the Department of Immunology, Allergy and Arthritis, Flinders Medical Centre; Arthritis Research Laboratory, Hanson Institute; Department of Rheumatology, The Queen Elizabeth Hospital; and Adelaide Institute for Sleep Health, Repatriation General Hospital, Adelaide, Australia. Supported by grants from the National Health and Medical Research Council and the Arthritis Foundation of Australia. J.G. Walker, FRACP; T.P. Gordon, MD; S. Waterman, PhD, Department of Immunology, Allergy and Arthritis, Flinders Medical Centre, Adelaide; S. Lester, BSc(Hons), Arthritis Research Laboratory, Hanson Institute, Adelaide; S. Downie-Doyle, PhD, Arthritis Research Laboratory, Hanson Institute and Department of Rheumatology, The Queen Elizabeth Hospital, Adelaide; R.D. McEvoy, FRACP, Adelaide Institute for Sleep Health, Repatriation General Hospital, Adelaide; K.D. Pile, MD, Department of Rheumatology, The Queen Elizabeth Hospital, Department of Medicine, The University of Adelaide; M. Rischmueller, FRACP, Department of Rheumatology, The Queen Elizabeth Hospital, Arthritis Research Laboratory, Hanson Institute. Address reprint requests to Dr. M. Rischmueller, Department of Rheumatology, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville, 5011 South Australia. E-mail: maureen.rischmueller@nwahs.sa.gov.au Submitted December 3, 2002; revision accepted April 2, 2003. |